HOME >> BIOLOGY >> NEWS
JCI table of contents -- March 8, 2006

EDITORS PICK: Therapeutic peptide frees the protein p73 to kill tumor cells

The protein p53 suppresses tumor development by potently inducing tumor cell death, making it an obvious target for anticancer therapeutics. However, this therapeutic approach is confounded by the fact that genetic mutations cause loss or inactivation of p53 in approximately 50% of human cancers. As the p53-related protein p73, which can also induce tumor cell death, is rarely mutated in human cancers, researchers from the Beatson Institute for Cancer Research, United Kingdom, hypothesized that it might represent a more viable target than p53 for the development of broadly applicable anticancer therapeutics.

In the study, which appears online on March 8 in advance of publication in the April print issue of the Journal of Clinical Investigation, Kevin Ryan and colleagues show that a peptide of 37 amino acids in length, which they generated from human p53 (termed 37AA), killed both p53-sufficient and p53-deficient human tumor cell lines. 37AA mediated tumor cell death by binding to the negative regulator of p53-family proteins iASPP and preventing it from repressing the death-inducing function of p73. Furthermore, systemic administration of 37AA to mice with established tumors of human origin (both p53-sufficient and p53-deficient tumors) induced tumor regression in a p73-dependent manner. These data suggest that targeting the p73-mediated pathway of tumor cell death might provide a new avenue of research for the development of anticancer therapeutics.

TITLE: A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo

AUTHOR CONTACT:
Kevin M. Ryan
Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Phone: +44-1413303655; Fax: +44-1419426521; E-mail: k.ryan@beatson.gla.ac.uk.

View the PDF of this article at:

Contact: Karen Honey
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
8-Mar-2007


Page: 1 2 3 4 5

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... MA (PRWEB) , ... December 09, 2016 , ... Aditya ... that in addition to Australia, Europe, and the United States, Axiomed is now gaining ... assure interest in this technology." , Mr. Humad went on to say that, “We ...
(Date:12/9/2016)... -- China Cord Blood Corporation (NYSE: CO ) ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... of its 2016 Annual General Meeting, which was held on ... . At the Annual General Meeting, ... Huazhen LLP as the independent auditors of the Company for ...
(Date:12/8/2016)... Board of Directors of the Pittsburgh Life Sciences ... only pure life sciences investment firm, today announced a ... developed by the Nominating and Governance Committee over the ... Jordan is selected to serve as President and ... who is elected to the position of Executive Chairman ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
Breaking Biology Technology:
Cached News: